What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

When U.S. Health Secretary Robert F. Kennedy Jr. announced on Aug. 5 that nearly $500 million to research mRNA vaccines would be canceled, it was one in a continuing line of moves that have put his ...

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing. “After a ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice within hours.

On first glance, the data that Health and Human Services Secretary Robert F. Kennedy Jr. cited to justify canceling some $500 million in federal grants for mRNA vaccine research looked impressive. The ...

The researchers found that mRNA-based COVID-19 vaccines could potentially help patients whose tumors don’t respond well to ...

University of Florida researchers found that advanced lung and skin cancer patients lived “significantly longer” after ...